Compositions and methods for activating innate and allergic immunity
AssigneeID Biomedical Corporation of Quebec
InventorsGeorge H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
Life of this patent
Estimating the term…
Loading patent…
AssigneeID Biomedical Corporation of Quebec
InventorsGeorge H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
Estimating the term…
Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).
A method for eliciting in a subject an antigen-independent, innate immune respond against a microbial infection that is a bacterial infection or a viral infection in a subject, said method comprising administering to the subject an immunostimulatory composition in an amount sufficient to elicit an antigen-independent, innate immune response, wherein the method is performed in the absence of administering an immunogenic composition comprising an antigen that elicits an adaptive antigen-specific response, wherein the immunostimulatory composition consists of Proteosomes and liposaccharide, wherein the Proteosome are obtained from Neiseria species and wherein the liposaccharide is obtained from the Neiseria species or from a different gram-negative bacteria species and wherein the causative agent of the microbial infection is (a) different from the Neisseria species from which the Proteosomes are obtained and (b) different from the gram-negative bacteria species from which the liposaccharide is obtained, and wherein the causative agent is a clinically relevant microorganism.
Dependencies are inferred from the claim text.